Skip to search formSkip to main contentSkip to account menu

sipuleucel-T

A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have… 
National Institutes of Health

Related topics

Related topics

13 relations
250 ML sipuleucel-T 200000 CELLS/ML Injection250 ML sipuleucel-T 200000 CELLS/ML Injection [Provenge]ACPP protein, humanAntigen Sensitization

Narrower (2)

APC 8015Provenge

Broader (1)

Tissue Extracts

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy
Control-arm patients from three prostate cancer clinical trials of sipuleucel-T (an autologous APC–based therapy) received APC… 
2013
2013
Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC).
34 Background: ADT is a standard therapy for pts with BRPC after failure of primary therapy, and has known immunomodulatory… 
Review
2012
Review
2012
An overview of sipuleucel-T: Autologous cellular immunotherapy for prostate cancer
Sipuleucel-T, the first autologous active cellular immunotherapy approved by the United States Food and Drug Administration, is… 
Review
2012
Review
2012
Development of novel immune interventions for prostate cancer.
2012
2012
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Vol. 104, Issue 18 | September 19, 2012 References 1. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of… 
2012
2012
Recent successes of cancer immunotherapy: a new dimension in personalized medicine?
Until recently, cancer therapy was limited to “debulking approaches” including surgery, chemo–radio- and hormono-therapy and… 
2011
2011
Characterization of antigen-specific T-cell activation and cytokine expression induced by sipuleucel-T.
155 Background: Sipuleucel-T (Provenge) is an autologous cellular immunotherapy designed to stimulate an immune response in men… 
2011
2011
Sipuleucel-T in African Americans: A subgroup analysis of three phase III sipuleucel-T trials in advanced prostate cancer.
e15148 Background: African American men are disproportionately affected by prostate cancer with an incidence of 231.9 for African… 
2011
2011
Post-progression treatment with APC8015F may have prolonged survival of subjects in the control arm of sipuleucel-T phase III studies.
4534 Background: Sipuleucel-T is an autologous cellular immunotherapy approved by the FDA for the treatment of asymptomatic or… 
Review
2008
Review
2008
Sipuleucel-T for the treatment of prostate cancer.
Patients with cancer have deficiencies in the number and function of dendritic cells. Loaded dendritic cell therapies attempt to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)